Journal
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
Volume 15, Issue 7, Pages 425-439Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41575-018-0010-0
Keywords
-
Categories
Funding
- EPoS (Elucidating Pathways of Steatohepatitis) consortium - European Union [634413]
- UK Medical Research Council
- UK National Institute for Health Research Newcastle Biomedical Research Centre
- excellence initiative (Competence Centres for Excellent Technologies - COMET) of the Austrian Research Promotion Agency FFG: Research Centre of Excellence in Vascular Ageing Tyrol, VASCage K-Project - BMVIT (Austrian Ministry for Transport, Innovation and [843536]
- BMWFW (Federal Ministry of Science, Research and Economy)
- Wirtschaftsagentur Wien
- Standortagentur Tirol
- University School of Medicine of Verona (Italy)
Ask authors/readers for more resources
Nonalcoholic fatty liver disease (NAFLD) is a common, progressive liver disease that affects up to one-quarter of the adult population worldwide. The clinical and economic burden of NAFLD is mainly due to liver-related morbidity and mortality (nonalcoholic steatohepatitis, cirrhosis or hepatocellular carcinoma) and an increased risk of developing fatal and nonfatal cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers (for example, colorectal cancer and breast cancer). Additionally, there is now accumulating evidence that NAFLD adversely affects not only the coronary arteries (promoting accelerated coronary atherosclerosis) but also all other anatomical structures of the heart, conferring an increased risk of cardiomyopathy (mainly left ventricular diastolic dysfunction and hypertrophy, leading to the development of congestive heart failure), cardiac valvular calcification (mainly aortic-valve sclerosis), cardiac arrhythmias (mainly atrial fibrillation) and some cardiac conduction defects. This Review focuses on the association between NAFLD and non-ischaemia-related cardiac disease, discusses the putative pathophysiological mechanisms and briefly summarizes current treatment options for NAFLD that might also beneficially affect cardiac disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available